Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (61-70 of 268) with videos related to

Pageof 27
Sort By:
JCO Precision Oncology|June 7, 2024
Serial Cell-Free DNA Sequencing in <i>ROS1</i> Fusion-Positive Lung Cancers During Treatment With EntrectinibNoura J Choudhury, Hyung Jun Woo, Monica Chen, et al.
Future Oncology (London, England)|June 20, 2025
A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it isAlexander Drilon, Jessica J Lin, Domnita-Ileana Burcoveanu, et al.
Ocular Oncology and Pathology|February 20, 2024
Mitogen-Activated Pathway Kinase Inhibitor-Associated Retinopathy: Do Features Differ with Upstream versus Downstream Inhibition?Jasmine H Francis, William Foulsham, Julia Canestraro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2020
Progresses Toward Precision Medicine in <i>RET</i>-altered Solid TumorsCarmen Belli, Santosh Anand, Justin F Gainor, et al.
Clinical Imaging|June 16, 2018
CT features of HER2-mutant lung adenocarcinomasPeter Sawan, Andrew J Plodkowski, Angela E Li, et al.
European Journal of Cancer (Oxford, England : 1990)|July 14, 2023
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing dataMatteo Repetto, Edoardo Crimini, Carmen Belli, et al.
Clinical Lung Cancer|November 7, 2019
Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung AdenocarcinomaMarissa S Mattar, Jason Chang, Ryma Benayed, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2023
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal FunctionMonica F Chen, Guilherme Harada, Dazhi Liu, et al.
JTO Clinical and Research Reports|July 3, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung CancerDaniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, et al.
JCO Precision Oncology|June 15, 2022
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine DeiodinaseLaura Boucai, Federico Salas-Lucia, Gnana P Krishnamoorthy, et al.
Pageof 27

Showing results (61-70 of 268) with videos related to

Sort By:
Pageof 27
JCO Precision Oncology|June 7, 2024
Serial Cell-Free DNA Sequencing in <i>ROS1</i> Fusion-Positive Lung Cancers During Treatment With EntrectinibNoura J Choudhury, Hyung Jun Woo, Monica Chen, et al.
Future Oncology (London, England)|June 20, 2025
A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it isAlexander Drilon, Jessica J Lin, Domnita-Ileana Burcoveanu, et al.
Ocular Oncology and Pathology|February 20, 2024
Mitogen-Activated Pathway Kinase Inhibitor-Associated Retinopathy: Do Features Differ with Upstream versus Downstream Inhibition?Jasmine H Francis, William Foulsham, Julia Canestraro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2020
Progresses Toward Precision Medicine in <i>RET</i>-altered Solid TumorsCarmen Belli, Santosh Anand, Justin F Gainor, et al.
Clinical Imaging|June 16, 2018
CT features of HER2-mutant lung adenocarcinomasPeter Sawan, Andrew J Plodkowski, Angela E Li, et al.
European Journal of Cancer (Oxford, England : 1990)|July 14, 2023
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing dataMatteo Repetto, Edoardo Crimini, Carmen Belli, et al.
Clinical Lung Cancer|November 7, 2019
Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung AdenocarcinomaMarissa S Mattar, Jason Chang, Ryma Benayed, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2023
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal FunctionMonica F Chen, Guilherme Harada, Dazhi Liu, et al.
JTO Clinical and Research Reports|July 3, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung CancerDaniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, et al.
JCO Precision Oncology|June 15, 2022
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine DeiodinaseLaura Boucai, Federico Salas-Lucia, Gnana P Krishnamoorthy, et al.
Pageof 27